Clinical trial
A Phase 2b, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT04266197 is registered in ClinicalTrials.gov with Respira Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Respira Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 25, 2020
- Completion date
- January 7, 2025
- Enrollment
- 42 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.